Pain Management in Cancer Patients

呂理駿 台大醫院雲林分院 腫瘤醫學部

Types of Pain

- Somatic pain
- Visceral pain
- Neuropathic pain

Somatic Pain

- Injury/damage to skin, muscle, or bone
- Bone metastasis
- Well-localized, sharp, stabbing, or throbbing
- Good response to treatment

Visceral Pain

- Organ injury/damage, hollow-organ obstruction, smooth-muscle spasm
- Poorly localized
- Referred pain
- Accompanying autonomic symptoms
- Often requires opioids

Neuropathic Pain

- Injury/damage to neural structures
- Dysesthesia
- Burning, tingling, shock-like
- Allodynia, hyperalgesia, hypalgesia
- Consider adjuvants

Pain Evaluation

• Before treatment:


evaluate the intensity, type, location, etiology, temporal factors, psychological issues and current analgesics

• After treatment

evaluate treatment response and decide further medication

Pain Intensity Evaluation

Numerical



Categorical

None (0), Mild (1-3), Moderate (4-6), or Severe (7-10)

Wong-Baker Faces Pain Rating Scale



Before Pain Management

- Remove exacerbating factors if possible
 - 1. Catheters
 - 2. Wound management
- Exclude oncological emergencies
 - 1. Bone fracture
 - 2. Brain metastasis; IICP
 - 3. Spinal cord compression
 - 4. Perforated organs

Pain Management

- Pharmacotherapy Analgesics Adjuvant drugs
- Palliative radiotherapy
- Nerve block; nerve stimulation
- Physical therapy
- Psychological therapy

WHO Analgesic Ladder

Severe

Strong Opioids ± Non-Opioids ± Adjuvant

morphine, fentanyl, meperidine

Moderate

Weak Opioids ± Non-Opioids ± Adjuvant

codeine, tramadol, buprenorphine, propoxyphene

Mild

Non-Opioids *±* Adjuvant

aspirin, acetaminophen, NSAIDs, COX-2 inhibitor

Non-Opioids

- Ceiling effects
- Most used in mild pain and somatic pain

Non-Opioids

Aspirin

generally not used for analgesia now due to side effects

 Acetaminophen (Panadol® 500mg) no anti-inflammation effect
 low side effect

Non-Opioids

 NSAIDS (Acemet[®], Naposin[®], Votan SR[®], Lacoxa SR [®], Reliflex [®], Surgam [®]) side effect: peptic ulcers; anti-platelet; renal function impairment avoid IV use • COX-2 inhibitors (Celebrex[®], Mobic[®]) mostly not covered by NHI side effects: CAD?

• Still have ceiling effects

 May interfere with effects of typical opioids (partial agonist, mixed agonist/antagonist)

• Codeine (15mg, 30mg) low analgesic effect q4-6h (up to 2# q4h) side effect sooner than analgesia • Tramadol (Tramal[®]) dual effect: µ morphine receptor agonist and monoamine reuptake inhibition minimal respiratory suppression Maximal: 400 mg/day oral (Tramal Retard® 100mg): q12h (up to 2# bid) IV (100mg): q6h (up to 1amp q6h)

• Buprenorphine (Temgesic[®]) mixed agonist/antagonist convenient sublingual use avoid combination with typical opioids Propoxyphene (Depain X[®]: also include 625mg acetaminophen) **CNS** depression weak analgesic effect no evidence of superiority over codeine avoid long-term use Maximal: 1# q4h

- Ultracet[®] (Acetaminopen + Tramal)
 - Tramal 37.5 mg
 - Acetaminophen 325 mg
 - Dose: 1~2# q6h po; max: 8# /day

- No ceiling effects
- Tolerance

clinically insignificant; dose increase parallels disease progression

Physical dependence

avoid sudden discontinuation, partial agonists and mixed agonist/antagonists

 Psychological dependence (addiction) seldom develops in patients taking opioids for pain relief

- Morphine HCI (oral 10mg, solution 0.1%, 0.5%, 1%) onset: 30 mins peak: 60 mins interval: q4h
- Morphine sulfate (MST[®] 60mg, morphine sulfate SR 30mg)
 - onset: 1hr
 - interval: q12h
- Fentanyl (Durogesic[®] 1.25mg, 2.5mg, 5mg/patch) onset: 6-12 hrs interval: q72h

Fentanyl

- Dosage proportional to the size
- 1.25 mg/patch → 12.5 µg/hr
 2.5 mg/patch → 25 µg/hr
 5 mg/patch → 50 µg/hr



 Meperidine (Demerol®) short-acting neurotoxic metabolite: norperidine euphoria → addiction avoid long-term use

Around-The-Clock with Breakthrough Dose as Needed

- Around-the-clock: long-acting medication
- Breakthrough dose: rapid onset, shortacting, easy-to-use medication
- Breakthrough dose = 10-20% of daily ATC daily dose
- Target: breakthrough ≤ 3 /day, severity<4

Administration Route

• IV administration used only when other methods are not feasible

Oral : IV = 30mg : 10mg

Patients Not under Current Opioids

• Pain 1-3

- acetaminophen, NSAIDs or COX-2 inhibitors
- weak opioids
- re-evaluation in 24-72 hours

Patients Not under Current Opioids

• Pain > 4: can still combine with non-opioids Oral 5-15 mg (IV 1-3 mg) short-acting morphine Re-evaluate in 60 mins (IV 15 mins) If pain > 7, double dose If pain 4-6, repeat the same dose If pain <3, prn use with previous dose Calculate daily dose, then decide Around-the-clock dose (ex. divided in 2 if use MST q12h), Breakthrough dose (10-20% of ATC dose q1h prn)

Patients under Current Opioids

- Pain 1-3: current breakthrough dose prn
- Pain > 4
 - Calculate previous breakthrough dose then add 50-100%
 - Re-evaluate in 60 mins (IV 15 mins)
 - Otherwise the same as the previous slides

Dose Conversion to Durogesic

Durogesic	Morphine oral (mg/day)	Morphine IV (mg/day)
2.5 mg/patch (25 µg/hr)	60	20
5 mg/patch (50 µg/hr)	120	40

Current long-acting morphine in NTUH: MST 60mg Morphine sulfate SR 30mg


Dose Conversion to Durogesic

Equivalent Dose Table

FENTANYL TRANSDERMAL SYSTEM DUCKED FRADEWARK 労 坦 尼 穿 皮 貼 片 劑 の 坦 尼 穿 皮 貼 片 劑		If Pain Persists	Equivalent Dose
		25 μg/h Q3D	25 mcg/h
Morphine	3 3 3 3 10mg 4# per day	333333 10mg 6# per day	60 mg/day
Ultracet	4# per day	6#~8# per day	6 tablets/day
Tramadol	50mg 4# per day	50mg 6# ~ 8# per day	300 mg/day
Codeine	C C C C C 30mg 4# per day	30mg 6# ~ 8# per day	200 mg/day

Pharmacokinetics of Durogesic

- Durogesic™ TTS 25 μg/h
- Durogesic™ TTS 50 μg/h
- ▲ Durogesic™ TTS 75 μg/h



Source: Reilly et al.: Abstracts: 7th World Congress on Pain, 1993, Abstract 841 (N91460)

Side Effects of Opioids

Constipation

- No tolerance
- Start stool softeners (MgO) and bowel stimulants (Dulcolax[®]) once start with opioids
- Adequate fluid intake
 - Lactulose if refractory
- Avoid stool-forming agents (Normacol[®])

Side Effects of Opioids

Nausea and vomiting

- Start tolerance in one week
- Antiemetics (Primperan[®], Motilium[®], Mopride[®]) when start with opioids or increase of dosage


Respiratory suppression

- Tolerance during dose titration
- Naloxone (0.4mg/amp) reversal
 - 0.1mg start, titration, q2-3mins repeat

Side Effects of Opioids

- Sedation and other neurological side effects (cognitive deficits, delirium, convulsions)
 - tolerance in one week
 - increase in patients with renal impairment
- Urine retention → medication control (Wecoli[®], Hytrin[®], Harnalidge[®])
- Pruritis → medication control

Adverse Effects of Durogesic



Source: Zech et al.: Pain 1992;50:293-301.

Adjuvant Medications for Specific Pain

- Pain associated with inflammation NSAIDs
- Bone pain NSAIDs, bisphosphonates, steroids
 Neuropathic pain antidepressants, anticonvulsants, topical agents

Take Home Message

- Always exclude emergent conditions first
- Remove exacerbating factors if possible
- Remember possible combination between non-opioids and opioids
- Adjuvant medication for specific pains

Take Home Message

- Good analgesic use Around-the-clock Breakthrough dose prn
 Avoid long term use of IV NSAID,
- buprenorphine, propoxyphene, meperidine
- Start side effect prevention on the start of opioid use

Reference

- National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: adult cancer pain
- 癌症疼痛處理指引, 國家衛生研究院, 2007

THANKS FOR YOUR ATTENTION!